Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Pharmaceutical company reports 3Q results, highlighted by launch of lead product
December 12th, 2004
Oscient Pharmaceuticals Corporation reported financial results for the third quarter ended Sept. 25, 2004. The quarter was highlighted by the Sept. 8, 2004, commercial launch of the company's lead product, Factive (gemifloxacin mesylate) tablets, for the treatment of acute bacterial exacerbations of chronic bronchitis (AECB) and mild to moderate community-acquired pneumonia (CAP). "By bringing an important new alternative for the treatment of CAP and AECB to the medical community, our new company attained its most exciting milestone to date," said Steven M. Rauscher, president and CEO of Oscient Pharmaceuticals. According to the...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
